Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Mereo Biopharma Group Plc ( (MREO) ) has provided an update.
Mereo BioPharma has announced updates on its lead clinical programs, including the ongoing Phase 3 study of setrusumab for osteogenesis imperfecta and the positive EMA opinion on alvelestat for alpha-1 antitrypsin deficiency-associated lung disease. The company is confident in the potential of setrusumab to become the standard-of-care and is prepared for key milestones through 2027, leveraging its cash runway and strategic partnerships. The Orphan Designation for alvelestat is a significant step towards its commercialization in Europe, promising benefits for patients with rare conditions.
More about Mereo Biopharma Group Plc
Mereo BioPharma is a clinical-stage biopharmaceutical company that specializes in developing innovative therapies for rare diseases. Its primary focus is on two product candidates: setrusumab, aimed at treating osteogenesis imperfecta, and alvelestat, targeting alpha-1 antitrypsin deficiency-associated lung disease. The company is involved in partnerships and licensing agreements to further its development and commercialization efforts.
YTD Price Performance: 3.80%
Average Trading Volume: 850,666
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $549.3M
For an in-depth examination of MREO stock, go to TipRanks’ Stock Analysis page.
